Acute leukemia of ambiguous lineage

Researchers test a reduced-intensity conditioning regimen before allogeneic stem cell transplant in adults with high-risk AML, MDS, or ALL who cannot tolerate standard intensive treatment. The regimen combines clofarabine, busulfan, and thymoglobulin. The trial measures relapse r…

This study tested a new drug called pelabresib in people with certain blood cancers, including myelofibrosis and leukemia. In the first part, the drug was given alone to find the safest dose. In the second part, it was given with or without another drug (ruxolitinib) to see if it…

This study tested whether removing a specific type of immune cell (naïve T cells) from donor stem cell grafts could prevent graft-versus-host disease (GVHD) after a stem cell transplant for blood cancers. The trial enrolled 84 patients who received high- or medium-intensity chemo…

This study tested whether adding the drug tocilizumab to standard care could reduce the risk of graft-versus-host disease (GVHD) after a cord blood transplant in adults with blood cancers. GVHD is a serious complication where donor cells attack the patient's body. Tocilizumab blo…

This early-stage trial tested the safety and best dose of flotetuzumab, an antibody drug, in 13 patients with advanced blood cancers that had come back or stopped responding to treatment. The drug works by blocking cancer cell growth. The main goal was to see what side effects oc…

This study tested a stem cell transplant from half-matched (haploidentical) family donors for 34 people with various blood cancers. Patients received a reduced-intensity conditioning regimen of fludarabine, melphalan, and total body irradiation before the transplant. The goal was…

This study tested adding a drug called thiotepa to the usual chemotherapy given before a donor stem cell transplant for people with leukemia. The goal was to see if this stronger mix could help more patients stay cancer-free one year after the transplant. The study included 40 ad…